Low-level light therapy and intense pulse light therapy in meibomian gland dysfunction. A systematic review and meta-analysis

IF 4.1 3区 医学 Q1 OPHTHALMOLOGY
Kai En Chan , Beth Shin Rei Lau , Blanche Xiao Hong Lim , Ruochen Du , Giuseppe Giannaccare , Louis Tong , Fiona Stapleton , Chris Hong Long Lim
{"title":"Low-level light therapy and intense pulse light therapy in meibomian gland dysfunction. A systematic review and meta-analysis","authors":"Kai En Chan ,&nbsp;Beth Shin Rei Lau ,&nbsp;Blanche Xiao Hong Lim ,&nbsp;Ruochen Du ,&nbsp;Giuseppe Giannaccare ,&nbsp;Louis Tong ,&nbsp;Fiona Stapleton ,&nbsp;Chris Hong Long Lim","doi":"10.1016/j.clae.2024.102344","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Meibomian gland dysfunction (MGD) is a leading cause of dry eye disease, affecting over a third of the global population. This disease is associated with ocular discomfort, reduced visual quality, and quality of life. Novel treatments like Intense Pulse Light (IPL) therapy and Low-Level Light Therapy (LLLT) have been reported to be useful in refractory MGD treatment. However, no systematic review has explored the utility of combining these two therapies.</div></div><div><h3>Methods</h3><div>Medline, Embase, and CENTRAL databases were searched for articles on LLLT + IPL therapy in MGD. A meta-analysis of single means was conducted to assess clinical endpoints.</div></div><div><h3>Results</h3><div>Analysis of 12 studies showed that LLLT + IPL therapy in MGD patients led to a significant decrease in Ocular Surface Disease Index score (MD: −22.8, 95 %CI: −29.1 to −16.5, I<sup>2</sup> = 97.5 %, p &lt; 0.001), and a significant increase in both Tear Break-up Time (MD: 2.2 s, 95 %CI: 0.9 s to 3.4 s, I<sup>2</sup> = 98.6 %, p &lt; 0.001) and Schirmer test (MD: 1.5 mm, 95 %CI: 0.6 mm to 2.5 mm, I<sup>2</sup> = 0.0 %, p = 0.001) at ≤ 3 months post treatment. These improvements were sustained in a sensitivity analysis at endpoints ≥ 6 months post treatment. While the percentage of loss of meibomian gland area (n = 4, MD: −3.8 %, 95 %CI: −7.2 % to −0.4 %, I<sup>2</sup> = 40.0 %, p = 0.031) was reported to be significantly reduced, this was not found to be sustained at endpoints ≥ 6 months post treatment (n = 2, MD: 5.9 %, 95 %CI: 1.8 % to 10.0 %, I<sup>2</sup> = 0.0 %, p = 0.005) in two studies.</div></div><div><h3>Conclusions</h3><div>This meta-analysis provides quantitative evidence supporting the clinical efficacy of LLLT + IPL therapy in MGD. Future research should evaluate its long-term safety and efficacy and compare it with alternative treatments.</div></div>","PeriodicalId":49087,"journal":{"name":"Contact Lens & Anterior Eye","volume":"48 2","pages":"Article 102344"},"PeriodicalIF":4.1000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Contact Lens & Anterior Eye","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1367048424002376","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Meibomian gland dysfunction (MGD) is a leading cause of dry eye disease, affecting over a third of the global population. This disease is associated with ocular discomfort, reduced visual quality, and quality of life. Novel treatments like Intense Pulse Light (IPL) therapy and Low-Level Light Therapy (LLLT) have been reported to be useful in refractory MGD treatment. However, no systematic review has explored the utility of combining these two therapies.

Methods

Medline, Embase, and CENTRAL databases were searched for articles on LLLT + IPL therapy in MGD. A meta-analysis of single means was conducted to assess clinical endpoints.

Results

Analysis of 12 studies showed that LLLT + IPL therapy in MGD patients led to a significant decrease in Ocular Surface Disease Index score (MD: −22.8, 95 %CI: −29.1 to −16.5, I2 = 97.5 %, p < 0.001), and a significant increase in both Tear Break-up Time (MD: 2.2 s, 95 %CI: 0.9 s to 3.4 s, I2 = 98.6 %, p < 0.001) and Schirmer test (MD: 1.5 mm, 95 %CI: 0.6 mm to 2.5 mm, I2 = 0.0 %, p = 0.001) at ≤ 3 months post treatment. These improvements were sustained in a sensitivity analysis at endpoints ≥ 6 months post treatment. While the percentage of loss of meibomian gland area (n = 4, MD: −3.8 %, 95 %CI: −7.2 % to −0.4 %, I2 = 40.0 %, p = 0.031) was reported to be significantly reduced, this was not found to be sustained at endpoints ≥ 6 months post treatment (n = 2, MD: 5.9 %, 95 %CI: 1.8 % to 10.0 %, I2 = 0.0 %, p = 0.005) in two studies.

Conclusions

This meta-analysis provides quantitative evidence supporting the clinical efficacy of LLLT + IPL therapy in MGD. Future research should evaluate its long-term safety and efficacy and compare it with alternative treatments.
低强度光治疗和强脉冲光治疗睑板腺功能障碍。系统回顾和荟萃分析。
背景:睑板腺功能障碍(MGD)是干眼病的主要原因,影响全球三分之一以上的人口。此病与眼部不适、视觉质量下降和生活质量有关。据报道,强脉冲光(IPL)疗法和低水平光疗法(LLLT)等新疗法可用于难治性MGD的治疗。然而,尚无系统综述探讨这两种疗法联合使用的效果。方法:检索Medline、Embase和CENTRAL数据库中有关LLLT + IPL治疗MGD的文章。采用单手段进行荟萃分析以评估临床终点。结果:12项研究分析显示,在MGD患者治疗后≤3个月,LLLT + IPL治疗可显著降低眼表疾病指数评分(MD: -22.8, 95% CI: -29.1 ~ -16.5, I2 = 97.5%, p 2 = 98.6%, p 2 = 0.0%, p = 0.001)。在治疗后≥6个月的终点,这些改善在敏感性分析中得以持续。虽然睑板腺面积损失的百分比(n = 4, MD: - 3.8%, 95% CI: - 7.2%至- 0.4%,I2 = 40.0%, p = 0.031)被报道显着减少,但在两项研究中,在治疗后≥6个月的终点(n = 2, MD: 5.9%, 95% CI: 1.8%至10.0%,I2 = 0.0%, p = 0.005)未发现这种情况持续。结论:本荟萃分析为支持LLLT + IPL治疗MGD的临床疗效提供了定量证据。未来的研究应评估其长期安全性和有效性,并与其他治疗方法进行比较。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.60
自引率
18.80%
发文量
198
审稿时长
55 days
期刊介绍: Contact Lens & Anterior Eye is a research-based journal covering all aspects of contact lens theory and practice, including original articles on invention and innovations, as well as the regular features of: Case Reports; Literary Reviews; Editorials; Instrumentation and Techniques and Dates of Professional Meetings.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信